Close Menu

NEW YORK (GenomeWeb) — Centogene said today that it has entered a 12-month strategic collaboration with Sarepta Therapeutics for the identification of patients with Duchenne muscular dystrophy in the Middle East and North Africa.

Under the terms of the agreement with Sarepta, Centogene will provide diagnostic services to physicians treating patients exhibiting symptoms related to DMD.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.